References
- Lewis V. Polycystic ovary syndrome: a diagnostic challenge. Infertil Reprod Med Clin North Am 2003; 14: 497–516
- Carmina E, Koyama T, Chang L, Stanczyk F Z, Lobo R A. Does ethnicity influence the prevalence of adrenal hyperandrogenism in insulin resistance in polycystic ovary syndrome?. Am J Obstet Gynecol 1992; 167: 1807–1812
- Ruutiainen K, Erkkola R, Gronroos M A, Irjala K. Influence of body mass index and age on the grade of hair growth in hirsute women of reproductive age. Fertil Steril 1998; 50: 260–265
- Zawadski J K, Dunaif A. Diagnostic criteria for Polycystic ovary syndrome: towards a rational approach. Polycystic ovary syndrome, A Dunaif, R Givens, F Haseltine. Blackwell Scientific, Boston 1992; 397–384
- Treloar A E, Boynton R E, Behn B G, Brown B W. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967; 12: 77–126
- Dewailly D. How many of the items in the polycystic ovary syndrome can be validated statistically?. Fertil Steril 2006; 85: 529
- Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to Polycystic ovary syndrome (PCOS). Hum Reprod 2004; 9: 41–47
- Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and IGT in polycystic ovary syndrome: a prospective controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165–169
- Taponen S, Martikainen H, Jarvelin M R, Laitinen J, Pouta A, Hartikainen L, Sovio U, McCarthy M I, Franks S, Roukonen A. Hormonal profile of women with self reported symptoms of oligomenorrhoea and/or hirsutism: North Finland Birth Cohort 1966 study. J Clin Endocrinol Metab 2003; 88: 141–147
- Salman K, Spielvogel R L, Miller J L, Rose L I. Androgens and oligomenorrhoea in hirsute women. J Am Acad Dermatol 1991; 24: 423–425
- Hasinski S, Telang G H, Rose L I, Pollock J L, Spielvogel R L, Miller J L. Testosterone concentration and oligomenorrhoea in women with acne. Int J Dermatol 1997; 36: 845–847
- Rickenlund A, Carlstrom K, Ekblom B, Brismar T B, von Schoultz B, Hirschberg A L. Hyperandrogenicity is an alternative mechanism underlying oligomenorrhoea or amenorrhoea in female athletes and may improve physical performance. Fertil Steril 2003; 79: 947–955
- Barth J H, Yasmin E, Balen A H. The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research. Clin Endocrinol 2007; 67: 811–815
- Hahn S, Kuehnal W, Tan S, Kramer K, Schmidt M, Roesler S, Kimmig R, Mann K, Janssen O E. Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome. Clin Chem Lab Med 2007; 45: 202–207
- Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escober-Morreale H F, Futterweit W, Janssen O E, Legro R S, Norman R J, Taylor R E, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006; 91: 4237–4245
- Adams J, Polson D W, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986; 293: 355–359